Contact Us
Drug Search Results
More Filters [+]

AP-325

Alternative Names: ap-325, ap 325, ap325
Latest Update: 2025-01-10
Latest Update Note: Clinical Trial Update

Product Description

AP-325 is being developed by Algiax Pharmaceuticals for the treatment of peripheral post-surgical neuropathic pain. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04429919?term=AP-325&draw=2&rank=2)

Mechanisms of Action: DHODH Inhibitor,GABA Modulator

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Algiax
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AP-325

Countries in Clinic: Belgium, Czech Republic, France, Germany, Spain

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Neuralgia|Neuropathic Pain|Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
GAP-325

P2

Completed

Type 2 Diabetes

2024-12-17

AP-325.04

P2

Completed

Neuralgia|Neuropathic Pain

2024-10-04

2019-003502-28

P2

Active, not recruiting

Neuropathic Pain

2021-06-14

Recent News Events

Date

Type

Title

02/04/2025

News Article

 Algiax Announces Positive Data from Phase 2a Proof of Concept Study Evaluating AP-325 in Patients with Neuropathic Pain

04/11/2024

News Article

 Algiax Pharmaceuticals Expands Phase 2a Study with Lead Candidate AP-325 in Chronic Neuropathic Pain with 12 New Clinical Sites in Belgium and France

09/21/2020

News Article

 Algiax Pharmaceuticals Announces First Patient Enrolled in Phase IIa Multi-center Proof-of-Concept Study Evaluating AP-325 in Chronic Neuropathic Pain

12/09/2019

News Article

 Algiax Is Ready to Go Into Proof-of-Concept for AP-325 and Welcomes New Investors

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions